Article
The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
Expert opinion on biological therapy - 1 Jan 2018
Panza Francesco, Seripa Davide, Lozupone Madia, Solfrizzi Vincenzo, Imbimbo Bruno P, Barulli Maria Rosaria, Tortelli Rosanna, Capozzo Rosa, Bisceglia Paola, Dimitri Andrea, Stallone Roberta, Dibello Vittorio, Quaranta Nicola, Daniele Antonio, Bellomo Antonello, Greco Antonio, Logroscino Giancarlo
Abstract excerpt
INTRODUCTION: The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer's disease (AD) suggested earlier intervention in the disease course. Secondary prevention trials have been started in autosomal-dominant AD (ADAD) individuals without cognitive dysfunction and in cognitively healthy subjects at risk of developing sporadic AD (SAD). AREAS COVERED: Herein, the authors discuss...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.